Harry Blackstone, DO
Family Medicine · Zephyrhills, FLNPI 1720016496
Payments from drug & device makers
Across 640 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$837
- AstraZeneca$834
- Amgen$829
- Pfizer$696
- Boehringer Ingelheim$531
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,554100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 149 | $1,855 |
| Lilly USA, LLC | 58 | $837 |
| AstraZeneca | 50 | $834 |
| Amgen | 64 | $829 |
| Pfizer | 47 | $696 |
| Boehringer Ingelheim | 31 | $531 |
| Johnson & Johnson(2 entities) | 30 | $466 |
| Novartis | 26 | $390 |
| GSK | 19 | $339 |
| Sanofi-aventis U.S. LLC | 20 | $334 |
| Amarin Pharma, Inc. | 15 | $295 |
| AbbVie | 18 | $292 |
| Sumitomo Pharma America, Inc. | 19 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $211 |
| Bayer | 8 | $188 |
| Dexcom, Inc. | 7 | $151 |
| Abbott | 8 | $145 |
| Merck | 8 | $99 |
| Astellas Pharma US Inc | 5 | $96 |
| Exact Sciences | 5 | $94 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| Kowa Pharmaceuticals America, Inc. | 6 | $78 |
| Nevro Corp. | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 6 | $65 |
| Boston Scientific | 3 | $62 |
| Eisai Inc. | 3 | $58 |
| Corcept Therapeutics | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lifescan, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $11 |
How this compares
$9,592 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $97,217 |
| JardianceEmpagliflozin | 76 | $93,327 |
| MounjaroTirzepatide | 35 | $53,985 |
| OzempicSemaglutide | 35 | $49,517 |
| XareltoRivaroxaban | 40 | $42,072 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $41,064 |
| FarxigaDapagliflozin Propanediol | 27 | $37,211 |
| Repatha SureclickEvolocumab | 31 | $34,716 |
| JanuviaSitagliptin Phosphate | 17 | $27,582 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $27,555 |
| LinzessLinaclotide | 21 | $22,606 |
| OxycontinOxycodone Hcl | 23 | $20,375 |
| MyrbetriqMirabegron | 22 | $20,164 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,315 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $5,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $696 | $97,21766 claims |
| Boehringer IngelheimJardiance | $531 | $93,32776 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $837 | $57,44949 claims |
| Novo NordiskOzempic | $1,855 | $49,51735 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $339 | $47,37954 claims |
| Johnson & JohnsonXarelto | $466 | $42,07240 claims |
| AstraZenecaFarxiga | $834 | $37,21127 claims |
| MerckJanuvia | $99 | $27,58217 claims |
| AbbVieLinzess, Synthroid | $292 | $25,13962 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $20,16422 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $4,851531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Zephyrhills
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.